Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Since April 2018 Andrew has been IBM’s Global Life Sciences Industry Leader.

Andrew helps clients address industry imperatives and save lives through the power of cognitive insights. He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Andrew was IBM’s Life Sciences Industry Leader for Europe between 2015-2108. Prior to transferring to Europe in July 2015, Andrew was IBM Life Sciences Industry Leader for China for 5 years. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company. He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business. Andrew has a Master of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.

Andrew is an advocate of sport and fitness as a gateway to good health. He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.

Christopher R. Lowe is Professor Emeritus of Biotechnology at the University of Cambridge and was founder Director of the Institute of Biotechnology at the University where he conducted multi-disciplinary research in both diagnostics and therapeutics in the healthcare biotechnology sector. He is a fellow of Trinity College, the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry. He has 398 peer-reviewed publications, 8 books and monographs, >100 patents, has supervised >95 PhD students and has a number of national and international prizes: “Queen’s Award for Technological Achievement”; “Queen’s Anniversary Prize for Higher and Further Education”; “Most Entrepreneurial Scientist of the UK”; OBE in the Queen’s New Year Honours; BBSRC Commercial Innovator of the Year in 2011.

Besides being a member of a number of Editorial Boards, Funding Bodies and Government Committees, he has been the driving force for the establishment of 12 spin-out companies including ProMetic Biosciences Inc, Cambridge Sensors Ltd, Smart Holograms Ltd, Paramata Ltd, Psynova Neurotech Ltd, LabXero Ltd, TumourVue Ltd and Royale Therapeutics Ltd., has a number of directorships and fosters entrepreneurship within the
University via a Master’s in Bioscience Enterprise, the University’s Seed Fund Committee (Cambridge Enterprise) and other Business School and student-led activities.

He is active in various overseas committees and in a number of legal and entrepreneurial roles. He is currently Director of the newly established Cambridge Academy of Therapeutic Sciences (CATS) within the University of Cambridge.

Dr Chris Torrance is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identification of novel drug targets for pharmaceutical development. By 2014 Dr Torrance and his colleagues had built Horizon into the fastest growing Biotech company
in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commercial and scientific staff and significant deal-flow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade in 2012.

Previously, Dr Torrance was Head of Oncology and Biology at the UK Biotechnology company Vernalis PLC (LSE: VER), where he was responsible for progressing several novel kinase oncology programs.

Dr Torrance has a bachelor’s degree in Biomedical Technology from Sheffield Polytechnic; a PhD in Biochemistry from East Carolina University (U.S.A) and completed Post-Doctoral training in the laboratory of Professor Bert Vogelstein at the Johns Hopkins University (U.S.A), where he pioneered the use of ‘X-MAN’ isogenic disease models in high-throughput screening and drug discovery.

In 2014, Dr Torrance and Dr Venkitaraman (Cambridge University) founded PhoreMost Ltd to develop a new technology platform solution to the next big issue in delivering Personalized Medicine, which is developing a toolbox of therapies big enough and affordable enough to impact the diverse array of key targets in cancer and other complex diseases, most of which are intractable to current drug discovery technologies.

Ian returned to the UK from Australia where he was Director of the ithree institute, University of Technology, Sydney to take up his role as Director of the Quadram Institute Bioscience (formerly Institute of Food Research) and Founding Director of the Quadram Institute in May 2015.

Ian has over 30 years’ experience in academic and commercial research.  His academic career has included being a founding member of The Wolfson Institute for BioMedical Research at University College London, one the UK’s first institutes of translational medicine. He has worked in the pharmaceutical industry at Glaxo Wellcome, and has founded biotech companies in the area of infectious disease, including Arrow Therapeutics, sold to AstraZeneca in 2007, and Auspherix, a venture capital backed company founded in 2013. He is also a Non-Executive Director for Genus plc.

Ian is an internationally recognised scientist and has expertise in infectious diseases, the microbiome, and its impact on health and wellbeing, genomics and metagenomics.

Jason is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, a Cambridge-based accelerator, he aims to identify and recruit the most disruptive healthcare start-ups worldwide, seed-fund them and leverage the exceptional resources of the Cambridge Cluster to de-risk and drive their success.

Previously, he was CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. While at Cambridge Epigenetix, Jason transformed the research tools company into a leading liquid biopsy player and led two successful fundraises (Series B and C) for a total of $51m.

Prior to joining Cambridge Epigenetix, Jason was a Business Development Manager for Horizon Discovery’s diagnostics division where he was responsible for developing and launching new reference standards for genomic clinical assays. He also served as an Associate at Cambridge Enterprise, the technology transfer office of the University of Cambridge, where he managed a broad intellectual property portfolio and fostered new spin-outs.

Jason was awarded a Marshall Scholarship to obtain his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodeling within coronary artery bypass grafts. He has a BSc (Summa Cum Laude) in Molecular Biology and Chemistry from Tulane University.

Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee.
 
As CCO, Joanne is responsible for Genomics England’s industry engagement strategy by developing, managing and accelerating relationships with commercial organisations − creating opportunities for collaboration both nationally and globally.
 
Joanne is a clinical academic and strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute in bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics.

Genomics England

The time for talking about the potential of genomic medicine is past. Genomics is not tomorrow. It’s here today. Genomics will transform patient outcomes and healthcare systems – and Genomics England is already moving to make a mainstream genomics medicine service a reality in the UK.
Realising this potential fully, however, demands more as this transformation can only take place with deep industry partnerships in place. Kick starting a UK genomics industry has been a core Genomics England aim from the outset. It recognises that − whilst NHS England, Genomics England and others build the data resources, infrastructure and systems − it is industry that develops the medicines, treatments and technologies that have such a big impact on patients’ lives. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective clinical service. The time for talking about genomic potential is past. The time to talk to business − and forge partnership on an industrial scale – is now.

John is Co-founder and CEO at Cambridge Cancer Genomics (CCG.ai), a precision AI start-up transforming the ability of oncologists to finally provide effective, personalised cancer treatment for everyone. John holds a PhD in functional genomics from the University of Cambridge and a Masters in Pharmacology from the University of Glasgow. His research career in academia (CRUK) and industry (MedImmune) focused on understanding how tumours evolve and become resistant to treatment. John is actively involved in the biotech startup community as a Venture Partner at the Pioneer Fund, Director of SiliconBio and a lecturer at Anglia Ruskin University.

John joined Johnson & Johnson in September 2016. In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders.

Prior to joining Johnson & Johnson, since November 2014, John was Head of Neuroscience and Mental Health at the Wellcome Trust.  Previous to that he worked at Eli Lilly and Company at their neuroscience research campus near London, UK.  At Lilly he led a team of labs dedicated to identifying new therapies for Alzheimer’s disease and schizophrenia.

John’s scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease.  John obtained a BSc in Pharmacology and Biochemistry at the University of Southampton in 1990 and remained at Southampton for his graduate work, studying mechanisms of epilepsy with Prof Howard Wheal.

In 1994 he joined Dr Robert Malenka’s laboratory at University of California San Francisco working on mechanisms of long-term synaptic plasticity in hippocampus and somatosensory cortex, also in close collaboration with Dr Roger Nicoll.  After completion of this post doc position, John joined Prof Graham Collingridge’s laboratory at the University of Bristol back in the UK in 1996, where he completed a one year post doc before establishing his own lab there. He rose up through the ranks to full Professor before leaving in 2004 to set up a lab at the Intramural Program at NINDS/NIH in Bethesda, MD, USA studying mechanisms and roles of synaptic plasticity in developing cortical circuits.

Dr. Joy Wolfram is an Assistant Professor at Mayo Clinic in Florida, where she leads the Nanomedicine and Extracellular Vesicles Laboratory. She also holds affiliate faculty positions in the Department of Nanomedicine at the Houston Methodist Hospital in Texas, the Department of Biology at the University of North Florida, and the Wenzhou Institute of Biomaterials and Engineering in China. She received her bachelor’s and master’s degrees in biology from the University of Helsinki in Finland. In 2016, she completed her Ph.D. in nanotechnology at the Chinese Academy of Sciences. In the past five years, she has authored over 40 publications and received more than 25 scientific awards from seven different countries. She was included in the Amgen Scholars Ten to Watch List, which highlights the best and brightest up-and-comers in science and medicine across 42 countries. Native of Finland, she was selected as one of 12 internationally accomplished Finns, alongside Nobel laureates. She was also listed on the Forbes 30 under 30 in healthcare in 2019. She is a board member and scientific advisor of several companies around the world with a cumulative customer base of over 18 million. She has designed many preclinical nanoparticles for the treatment of various diseases, including cancer. Her goal is to develop innovative nanomedicines
that bring the next generation of treatments directly to the clinic. Her mission is also to inspire and support underrepresented minorities in science. She is actively involved in community outreach and scientific education, including serving as the co-chair of the Physical Sciences-Oncology Network Education and Outreach Working Group of the National Cancer Institute in the United States. As a TEDx and Hello Tomorrow speaker she strives to bring science to a wider audience.

After studying Management and Economics and Interior Architecture and starting to work within the start-up scene Magdalena founded the I.E.C.T. – Hermann Hauser together with Josef, Johannes and Hermann Hauser in 2016. They focus on providing access to international know-how and smart money. Since February 2018 she took the position of CEO and became proxy for the Hermann Hauser’s investment vehicle. Her main activities contain amongst others running the investment process, developing new programmes to foster entrepreneurship within the research and science society and building up a start-up friendly ecosystem with national and international partners. Alongside Magdalena works as mentor and coach for different programmes and is co-founder of the non-profit association AI Austria - Austrian Society for Artificial Intelligence.

Dr. Maria Chatzou holds a PhD in Biomedicine, MSc in Bioinformatics and BSc in Computer Science and Biomedical Informatics. She is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing (HPC). She is also a passionate entrepreneur. She has already founded two companies, Innovation Forum Barcelona and the Techstars-backed Lifebit.

As a researcher at the Centre for Genomic Regulation, in Barcelona, Spain, she designed and deployed tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalised medicine. She was also part of the developing team of Nextflow, a programming framework that is revolutionising the computational analysis of genomic data. 

Dr. Chatzou is a frequent industry speaker and has spoken on the subject of HPC, Cloud & Big Data, Genomics Workflows, Personalized Medicine, Women in Leadership, Entrepreneurship, Start-Ups and Deep Tech Innovation in many international conferences.

Peter McNaughton was born in New Zealand, where he studied Physics at the University of Auckland. He was lecturer in Physiology at the University of Cambridge from 1978 to 1991, and moved to London in 1991 as Head of Physiology at King’s College London. In 1999 he moved to Cambridge as Head of the Department of Pharmacology and in 2013 returned to King’s College London as Professor of Pharmacology.

He has worked in several areas of neuroscience, mainly in the cellular basis of sensations – vision, pain and magnetic sensation. The principal interests of his lab at present are the molecular and cellular bases of pain, thermal sensation and thermo-regulation. His work connects pain and thermal sensation at the level of molecular detectors to the behaviour of the whole animal. He has initiated two drug development projects, both arising from discoveries in his lab.

Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. In addition to clinical training he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, He heads a clinical research group undertaking trials into renal
cancers and also a range of early phase clinical trials of biological agents. He also leads a group undertaking translational research into immunotherapy of cancer with a focus on adoptive cell therapy. In addition, to pre-clinical research he has developed a GMP cell therapy unit to provide clinical grade cell manufacturing – this is now a commercial spinout company (Cellular Therapeutics Ltd). He is/has been the coordinator of several major European Union consortia in this field including the on-going clinical trials project (www.ATTACK-cancer.eu). He has published widely in scientific and clinical journals.

Tom Simmons is Founder and CEO of Cambridge Glycoscience, whose mission is to tackle excessive sugar consumption worldwide. They do this by developing natural ingredients that can be used to reduce sugar across the food system. Tom was previously a Royal Society of Edinburgh Enterprise Fellow and a World Economic Forum Global Futures Council Fellow, both at the University of Cambridge.

Dr. Vishal Gulati is a venture capital investor focusing on the convergence of healthcare/biology with internet, AI, and engineering. Vishal has led Draper Esprit’s investments into some of Europe’s leading companies in these sectors including Clue, PushDr, Lifesum, Ieso Digital Health, Fluidic Analytics, and Evonetix. He is also an investor in Kheiron Medical, Repositive, Mimi Hearing Technologies, Quit Genius, MyRecovery, Closed Loop Medicine, Turbine and Project Sapien.

In addition to Vishal’s role at Draper Esprit, he is an independent director on the board of two publicly listed companies, Horizon Discovery (Cambridge) and Sensyne Health (Oxford) and is chairman of Digital Health Forum and serves on Innovate UK’s Major Award Committee. Vishal also mentors first time founders who are leaving academic careers to start technology businesses.
Prior to this Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital. Vishal received his postgraduate medical training at centres including the Nuffield Department of Medicine (Oxford) and Department of Medicine (St Mary’s Hospital, London) as a Rhodes Scholar.

Dr. Claude Bertrand graduated in pharmacy (Pharm.D.) from Strasbourg University, France, and has obtained his PhD in Strasbourg with research in the fields of immuno-pharmacology and neurogenic inflammation. After a 2-year post-doctoral appointment at the University of California, San Francisco, Claude joined the allergy and asthma unit at Ciba-Geigy (later Novartis) in Basel. In 1996, he moved to the Inflammatory Disease Unit at Roche Bioscience in Palo Alto, California where he became Head of the In-vivo Pharmacology Group and was responsible for supporting projects in rhumatology and respiratory diseases. In 1999, he was recruited as Director of Biology for Inflammation, GI and Pain at Parke-Davies, which later became part of Pfizer where he was heading Drug Discovery. In 2004, Dr. Bertrand joined AstraZeneca as Vice-President of Discovery for Respiratory and Inflammation Research at Alderley Park, UK and in 2005 was appointed Global Senior Vice President for Respiratory and Inflammation Research Area overseeing R&D activities at three sites in the UK and Sweden. In 2009, Dr. Bertrand joined Ipsen, France, as Executive Vice-President, Chief Scientific Officer and has been since June 2011, Executive Vice-President for Research & Development, Chief Scientific Officer with a focus on oncology, neurology and endocrinology. In March this year, Claude was appointed General Director R&D, Chief Scientific Officer at Servier.

With a degree in Law and French and a postgraduate diploma in European marketing, Jeanette’s early career was in international business development. Prior to joining the Cambridge Science Park in 2017, Jeanette was Project Director at the Cambridge Biomedical Campus where she helped attract companies including AstraZeneca to the Campus, and created a strong sense of community - an achievement recognised by winning Property Week’s prestigious Place Making Award in 2014. At the Cambridge Science Park, Jeanette is spearheading marketing, community building and master planning. In her first year she was instrumental in securing a £200m investment in the Science Park from TUS-Holdings of Beijing, China.

Sir Leszek was appointed as a Trustee to Cancer Research UK in July 2016 and as Chairman in November 2016.
Following a distinguished academic and clinical research career and prior to his appointment as Vice-Chancellor at the University of Cambridge in 2010, Sir Leszek’s roles included Chief Executive of the Medical Research Council and Deputy Rector of Imperial College London. He was also a founding Fellow of the Academy of Medical Sciences. His work in vaccines included Europe’s first trial of a vaccine for human papillomavirus to treat cervical cancer, research conducted at the University of Cardiff and funded by Cancer Research UK.
He was knighted in 2001 for his pioneering work in vaccines.

iMed.UL. Universidade de Lisboa, Portugal
SilvaLima Preklinika Limited, United Kingdom

Maria Beatriz Silva Lima is PharmD and PhD in Pharmacology and is full professor of Pharmacology and Regulatory Science at the Universidade de Lisboa, Faculty of Pharmacy, and head of the Department of Pharmacological Sciences.

She is the Coordinator of the research Group of Pharmacological Sciences of the iMed.UL - RESEARCH INSTITUTE FOR MEDICINES AND PHARMACEUTICAL SCIENCES, where she heads also the research Group in Nonclinical Safety and Regulatory Science.
Beatriz Silva Lima has more than 20 years of experience as an expert in nonclinical and regulatory science at the medicines agency in Portugal, Infarmed, and at the EMA, UK. She has been up to July 2012 member of the Committee of Human Medicines (CPMP/CHMP), Committee of Advanced Therapies (CAT) and Scientific Advice Working Party (SAWP). She acted as the Portuguese (Co)Rapporteur of multiple centralized applications and as coordinator of a high number of European Scientific Advices/Protocol Assistance in areas like nonclinical, neurology, oncology, covering small molecules and ATMPs or Biopharmaceuticals. She has been Chair of the Safety Working Party (SWP) for 12 years, has co-Chaired with Dr Jean Louis Robert the EMA Nonclinical Expert Group on Nanomedicines, responsible for elaboration of several reflection papers in the area, and has been involved as Co-Deputy in ICH discussions on ICH M3R2, S6R1 and S1 guidelines on behalf of the European Commission. Since October 2012 she consults on nonclinical drug development strategies. She acts also a nonclinical expert and member of the NDA Advisory Board, Sweden. Since January 2014 up to October 2018 she Chaired the Scientific Committee of the Innovative Medicines Initiative (IMI).
Areas of research: Regulatory Science Nonclinical Safety; Oncology, Pharmacology of metabolic diseases;
Furthermore, Beatriz Silva Lima is highly involved in international education in the area of regulatory science. I) She Coordinates a second cycle Master Course on Regulatory Science in the Faculty of Pharmacy of the Universidade de Lisboa (RAMPS), ii) she Co-coordinates with Prof Per Spindler (University of Copenhagen) and Dr Kirstin Meyer (Bayer Healthcare) a Nonclinical Module on Regulatory Guidelines of the European Master Course (IMI sponsored) SafeSciMet, iii) and of a similar master also IMI sponsored ECMDC, led by the Semelweiss University, Hungary, iv) she integrates the PharmaTrain Course EUDIPHARM lead by the University of Lyon, and she contributes as faculty to the Atrium Regulatory Course on Regulatory Aspects as well as to the MIND course (University of Copenhagen). Beatriz Silva Lima integrates the EUPATI (European Patient Academy, IMI-funded project) Portuguese/National Platform, and she is a member of the Steering Committee of the European National Platform of EUPATI (European Patient Academy for Therapeutic innovation), thus Co-Chairing the Executive Committee.
Beatriz Silva Lima also integrates several working groups/ projects within the EPAA (European Partnership for Animal Alternatives), NC3Rs UK, and ILSI – HESI, US and is Editor in Chief of the Regulatory Science Section of the Journal Frontiers.

Dr. Rory O'Connor qualified in Medicine from the University of Liverpool in 1978 and trained in Cardiology and General Medicine before joining the pharmaceutical industry in 1989. He has been with Pfizer for 19 years, originally with Global Research ＆ Development in Sandwich UK, working in neuroscience development with responsibility for antipsychotic and neuroprotective agents. In 1996 he moved to Pfizer HQ in New York as Medical Director Neuroscience, leading the strategic development and launch of a novel antipsychotic, including direction of the associated global phase IIIb/IV clinical program. In 2000 he assumed responsibility for Medical Affairs for Pfizer’s European operations, based in New York. In 2009 he returned to Europe from New York as Vice-President, Medical Affairs, Primary Care Business Unit for Europe. In January 2014 he was appointed Senior Vice-President, Head of Global Medical Affairs, Global Innovative Pharma Business.
He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).

Sonia is an HEC business school graduate. Whilst studying at HEC, she simultaneously studied at AgroParistech where she obtained a Master’s degree in genetics. She then gained a PhD in molecular and cellular biology from Paris University, specialising in gene therapy. She decided to start her career in academia and became assistant professor at CentraleSupelec where she taught biology and co-founded a research group in mathematical biology applied to biological systems. During that time, she coordinated European FP6 projects and co-led collaborative projects with both public (CEA, CNRS, École Normale Supérieure de la rue d'Ulm...) and private (Les Laboratoires Servier, Genzyme...) partners. She also founded the biology student club which organised extracurricular activities around the discipline. In 2007, she joined Rothschild and Cie where she performed both origination and execution activities in Mergers and Acquisitions. She took part in transactions in several industrial sectors and strengthened her financial skills and experience whilst offering healthcare customers an in depth knowledge of their industry and technological issues. Following her investment banking experience, she became a Business Development professional within Ipsen. Initially in charge of the financial modelling team, she then led late stage oncology BD and finally moved to the UK to become Head of early stage business development. During her years at Ipsen, she originated and/or executed several strategic deals, led the negotiation of a spin out and coordinated several initiatives around process optimisation. She has recently joined DNB, one of the leading Nordic banks, to become Head of Healthcare CEMEA. She carries out strategic advisory and financing transactions for large companies among other activities as she covers all available products and services offered by DNB.
Sonia also has a green belt in operational excellence and was nominated in the BioBeats Movers and Shakers list in 2016. A mother of two and ballet enthusiast (both watching and practicing), she is also an active member of W.I.T.H. (Women Innovating Together in Healthcare).

Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge. He is founder/director of the Milner Therapeutics Institute and deputy director of the Gurdon Institute.

Tony did his PhD at the University of Cambridge and postdoctoral work at MRC Laboratory of Molecular Biology and New York University Medical Center. His research group at the Gurdon Institute is focused on epigenetic modifications and their involvement in cancer.

Tony is founder/director of Cambridge Gravity, a philanthropic vehicle for science at the University of Cambridge. He is the founder of a cancer charity "Vencer el Cancer" (Conquer Cancer) based in Spain. He is on the Scientific Advisory Board of the Institute of Cancer Research (UK) and the Andalucian Centre for Molecular Biology and Medicine, CABIMER (Spain).

Tony is a co-founder and director (1998-2012) of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and director (2001-2003) of Chroma Therapeutics, of a drug discovery company based in Oxford and a co-founder and director (2016-) of STORM Therapeutics, a drug discovery company based in Cambridge.

Tony has been elected member of the European Molecular Biology organization, is a Fellow of the British Academy of Medical Sciences (FMedSci), Fellow of the Royal Society (FRS), Fellow of the American Academy of Arts and Sciences and is a Cancer Research UK Gibbs Fellow. He has been awarded the Wellcome Trust medal for research in biochemistry related to medicine (UK), the Tenovus Medal (UK), the Bodossaki Foundation prize in Biology (Greece), the Bijvoet Medal (Holland), the Biochemical Society Award Novartis Medal and Prize (UK) and the Heinrich Wieland Prize (Germany).